Revisiting inconsistency in large pharmacogenomic studies
Open accessThe DOI matches its Crossref record.
Abstract
In 2013, we published a comparative analysis mutation and gene expression profiles and drug sensitivity measurements for 15 drugs characterized in the 471 cancer cell lines screened in the Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Cell Line Encyclopedia (CCLE). While we found good concordance in gene expression profiles, there was substantial inconsistency in the drug responses reported by the GDSC and CCLE projects. We received extensive feedback on the comparisons that we performed. This feedback, along with the release of new data, prompted us to revisit our initial analysis. Here we present a new analysis using these expanded data in which we address the most significant suggestions for improvements on our published analysis — that targeted therapies and broad cytotoxic drugs should have been treated differently in assessing consistency, that consistency of both molecular profiles and drug sensitivity measurements should both be compared across cell lines, and that the software analysis tools we provided should have been easier to run, particularly as the GDSC and CCLE released additional data. Our re-analysis supports our previous finding that gene expression data are significantly more consistent than drug sensitivity measurements. The use of new statistics to assess data consistency allowed us to identify two broad effect drugs and three targeted drugs with moderate to good consistency in drug sensitivity data between GDSC and CCLE. For three other targeted drugs, there were not enough sensitive cell lines to assess the consistency of the pharmacological profiles. We found evidence of inconsistencies in pharmacological phenotypes for the remaining eight drugs. Overall, our findings suggest that the drug sensitivity data in GDSC and CCLE continue to present challenges for robust biomarker discovery. This re-analysis provides additional support for the argument that experimental standardization and validation of pharmacogenomic response will be necessary to advance the broad use of large pharmacogenomic screens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 33
- M Garnett, 2012, Systematic identification of genomic markers of drug sensitivity in cancer cells., Nature., 483, 570-5, 10.1038/nature11005 · DOI · Paper page
- J Barretina, 2012, The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity., Nature., 483, 603-7, 10.1038/nature11003 · DOI · Paper page
- S Papillon-Cavanagh, 2013, Comparison and validation of genomic predictors for anticancer drug sensitivity., J Am Med Inform Assoc., 20, 597-602, 10.1136/amiajnl-2012-001442 · DOI · Paper page
- Z Dong, 2015, Anticancer drug sensitivity prediction in cell lines from baseline gene expression through recursive feature selection., BMC Cancer., 15, 489, 10.1186/s12885-015-1492-6 · DOI
- I Jang, 2014, Systematic assessment of analytical methods for drug sensitivity prediction from cancer cell line data., Pac Symp Biocomput., 63-74, 10.1142/9789814583220_0007 · DOI · Paper page
- I Cortés-Ciriano, 2016, Improved large-scale prediction of growth inhibition patterns using the NCI60 cancer cell line panel., Bioinformatics., 32, 85-95, 10.1093/bioinformatics/btv529 · DOI · Paper page
- B Haibe-Kains, 2013, Inconsistency in large pharmacogenomic studies., Nature., 504, 389-93, 10.1038/nature12831 · DOI · Paper page
- C Hatzis, 2014, Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward?, Cancer Res., 74, 4016-23, 10.1158/0008-5472.CAN-14-0725 · DOI · Paper page
- Z Safikhani, 2016, Assessment of pharmacogenomic agreement [version 1; referees: 3 approved]., F1000 Res., 5, 825, 10.12688/f1000research.8705.1 · DOI
- P Haverty, 2016, Reproducible pharmacogenomic profiling of cancer cell line panels., Nature., 533, 333-7, 10.1038/nature17987 · DOI · Paper page
- P Smirnov, 2016, PharmacoGx: an R package for analysis of large pharmacogenomic datasets., Bioinformatics., 32, 1244-6, 10.1093/bioinformatics/btv723 · DOI · Paper page
- H Hong, 2012, Technical reproducibility of genotyping SNP arrays used in genome-wide association studies., PLoS One., 7, e44483, 10.1371/journal.pone.0044483 · DOI
- M Yu, 2015, A resource for cell line authentication, annotation and quality control., Nature., 520, 307-11, 10.1038/nature14397 · DOI · Paper page
- A Goodspeed, 2015, Tumor-derived Cell Lines as Molecular Models of Cancer Pharmacogenomics., Mol Cancer Res., 14, 3-13, 10.1158/1541-7786.MCR-15-0189 · DOI · Paper page
- 2015, Pharmacogenomic agreement between two cancer cell line data sets., Nature., 528, 84-7, 10.1038/nature15736 · DOI · Paper page
- W Youden, 1950, Index for rating diagnostic tests., Cancer., 3, 32-5, 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3 · doi:10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3
- K Pearson, 1895, Note on Regression and Inheritance in the Case of Two Parents., Proc R Soc Lond., 58, 240-2
- C Spearman, 1987, The proof and measurement of association between two things. By C. Spearman, 1904., Am J Psychol., 100, 441-71
- R Somers, 1962, A New Asymmetric Measure of Association for Ordinal Variables., Am Sociol Rev., 27, 799-811, 10.2307/2090408 · DOI · Paper page
- B Matthews, 1975, Comparison of the predicted and observed secondary structure of T4 phage lysozyme., Biochim Biophys Acta., 405, 442-51, 10.1016/0005-2795(75)90109-9 · DOI · Paper page
- A Hudson, 2014, Discrepancies in cancer genomic sequencing highlight opportunities for driver mutation discovery., Cancer Res., 74, 6390-6, 10.1158/0008-5472.CAN-14-1020 · DOI
- F Harrell, 1982, Evaluating the yield of medical tests., JAMA., 247, 2543-6, 10.1001/jama.1982.03320430047030 · DOI · Paper page
- L MAQC Consortium, Shi, 2006, The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements., Nat Biotechnol., 24, 1151-61, 10.1038/nbt1239 · DOI · Paper page
- L Shi, 2010, The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models., Nat Biotechnol., 28, 827-38, 10.1038/nbt.1665 · DOI · Paper page
- N Pozdeyev, 2016, Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies., Oncotarget., 7, 51619-51625, 10.18632/oncotarget.10010 · DOI
- R Irizarry, 2003, Exploration, normalization, and summaries of high density oligonucleotide array probe level data., Biostatistics., 4, 249-64, 10.1093/biostatistics/4.2.249 · DOI · Paper page
- W de Leeuw, 2008, Salvaging Affymetrix probes after probe-level re-annotation., BMC Res Notes., 1, 66, 10.1186/1756-0500-1-66 · DOI
- S Carter, 2012, Absolute quantification of somatic DNA alterations in human cancer., Nat Biotechnol., 30, 413-21, 10.1038/nbt.2203 · DOI · Paper page
- C Wilks, 2014, The Cancer Genomics Hub (CGHub): overcoming cancer through the power of torrential data., Database (Oxford)., 2014, 10.1093/database/bau093 · DOI · Paper page
- C Trapnell, 2012, Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks., Nat Protoc., 7, 562-78, 10.1038/nprot.2012.016 · DOI · Paper page
- A Bairoch, 2015, ExPASy - Cellosaurus [Internet]., Cellosaurus.
- Y Benjamini, 1995, Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing., J R Stat Soc Series B Stat Methodol., 57, 289-300, 10.1111/j.2517-6161.1995.tb02031.x · DOI · Paper page
- Z Safikhani, 2016, Dataset: Revisiting inconsistency in large pharmacogenomics studies., Open Science Framework.
Cited by
Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs
Hafner, M., Niepel, M., Chung, M., & Sorger, P. K. (2016) · Nature Methods · doi:10.1038/nmeth.3853 · Cited by 681
Mitochondrial metabolism promotes adaptation to proteotoxic stress
Tsvetkov, P., Detappe, A., Cai, K., Keys, H. R., Brune, Z., Ying, W., Thiru, P., Reidy, M., Kugener, G., Rossen, J., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0291-9 · Cited by 645
A review of connectivity map and computational approaches in pharmacogenomics
Musa, A., Ghoraie, L. S., Zhang, S.-D., Galzko, G., Yli-Harja, O., Dehmer, M., Haibe-Kains, B., & Emmert-Streib, F. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbw112 · Cited by 260
Self-citationPharmacoDB: an integrative database for mining in vitro anticancer drug screening studies
Smirnov, P., Kofia, V., Maru, A., Freeman, M., Ho, C., El-Hachem, N., Adam, G.-A., Ba-alawi, W., Safikhani, Z., & Haibe-Kains, B. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx911 · Cited by 155
Self-citationSuphavilai, C., Chia, S., Sharma, A., Tu, L., Da Silva, R. P., Mongia, A., DasGupta, R., & Nagarajan, N. (2021) · Genome Medicine · doi:10.1186/s13073-021-01000-y · Cited by 58
“Several sources of noise in drug response measurement experiments have been reported in previous studies, including lack of experimental replication [14, 15], and discordance in drug response information that was generated based on the same set of cell lines [59].”
Background
Metadata
- Authors
- Safikhani, Z., Smirnov, P., Freeman, M., El-Hachem, N., She, A., Rene, Q., Goldenberg, A., Birkbak, N. J., Hatzis, C., Shi, L., Beck, A. H., Aerts, H. J. W. L., Quackenbush, J., & Haibe-Kains, B.
- Venue
- F1000Research
- Publisher
- F1000 Research Ltd
- Published
- 2016-09-16
- Volume
- 5
- Pages
- 2333
- ISSN
- 2046-1402 (ISSN-L)
- OpenAlex
- W4234509242
- Cited by
- 96
- References
- 0
- FWCI
- 9.82
- Type
- journal article
- Language
- en
- Update notices
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Revisiting inconsistency in large pharmacogenomic studies. https://app.cochat.ai/papers/10.12688/f1000research.9611.1
- The paper
- Safikhani, Z., Smirnov, P., Freeman, M., El-Hachem, N., She, A., Rene, Q., Goldenberg, A., Birkbak, N. J., Hatzis, C., Shi, L., Beck, A. H., Aerts, H. J. W. L., Quackenbush, J., & Haibe-Kains, B. (2016). Revisiting inconsistency in large pharmacogenomic studies. F1000Research. https://doi.org/10.12688/f1000research.9611.1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.